AssetMark Inc
NAMS icon

AssetMark Inc’s NewAmsterdam Pharma NAMS Stock Holding History

AssetMark Inc’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-96
Closed -$2.47K – 2712
2024
Q4 		$2.47K Buy
+96
New +$2.04K ﹤0.01% 2076

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

AssetMark Inc's NAMS Position: Q1 2025 in Review

AssetMark Inc sold out of NewAmsterdam Pharma (NAMS) in Q1 2025, closing a stake of 96 shares — an estimated $2.47K sold.

AssetMark Inc first reported a position in NAMS in Q4 2024 and held it in 1 quarter. The position peaked at $2.47K in Q4 2024. 126 funds tracked by Wall St. Rank hold NAMS as of Q1 2025.

  • AssetMark Inc reported no remaining NewAmsterdam Pharma position as of Q1 2025 after selling out during the quarter.
  • AssetMark Inc sold 96 NewAmsterdam Pharma shares in Q1 2025, an estimated $2.47K.
  • AssetMark Inc first reported a position in NewAmsterdam Pharma in Q4 2024 and held it in 1 quarter.
  • AssetMark Inc's NewAmsterdam Pharma position peaked at $2.47K in Q4 2024.
  • 126 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2025.

Based on AssetMark Inc's 13F filing for Q1 2025, filed 6 May 2025.